TABLE 1.
Characteristics of HBV-HIV Co-infected North American Adult Sample and the Biopsy Subsample
| Analysis Sample (n = 114)* | Biopsy Subsample (n = 62)* | |
|---|---|---|
| Variable | n (%)† | n (%)† |
| Age (years) | ||
| Median (IQR) | 49 (45: 55) | 50 (46: 54) |
| Sex | ||
| Male | 104 (91.2%) | 58 (93.5%) |
| Female | 10 (8.8%) | 4 (6.5%) |
| Race | n = 111 | n = 60 |
| Non-Hispanic White | 36 (32.4%) | 17 (28.3%) |
| Non-Hispanic Black | 57 (51.4%) | 32 (53.3%) |
| Non-Hispanic Asian | 5 (4.5%) | 4 (6.7%) |
| Other | 13 (11.7%) | 7 (11.7%) |
| Coffee of cups per day | n = 111 | n = 60 |
| None to <1 per day | 56 (50.5%) | 31 (51.7%) |
| 1 to 2 per day | 37 (33.3%) | 17 (28.3%) |
| 3 or more per day | 18 (16.2%) | 12 (20.0%) |
| Alcohol | n = 113 | n = 61 |
| None | 63 (55.8%) | 31 (50.8%) |
| Moderate | 35 (31.0%) | 24 (39.3%) |
| At risk | 15 (13.3%) | 6 (9.8%) |
| BMI (kg/m2) | n = 109 | n = 60 |
| Median (IQR) | 25.9 (22.5–30.3) | 25.8 (22.7–29.1) |
| Weight status (race-adjusted) | n = 109 | n = 60 |
| Under/normal | 44 (40.4%) | 24 (40.0%) |
| Overweight | 37 (33.9%) | 25 (41.7%) |
| Obese | 28 (25.7%) | 11 (18.3%) |
| Lipodystrophy grade | n = 103 | n = 56 |
| None | 87 (84.5%) | 45 (80.4%) |
| Mild | 10 (9.7%) | 7 (12.5%) |
| Moderate or severe | 6 (5.8%) | 4 (7.1%) |
| DM | 10 (8.8%) | 4 (6.5%) |
| Hyperlipidemia | 34 (29.8%) | 17 (27.4%) |
| Sexually transmitted HBV or HIV | n = 106 | n = 57 |
| 101 (95.3%) | 57 (100.0%) | |
| Estimated duration of HIV or HBV infection (years) | n = 107 | n = 57 |
| Median (IQR) | 20 (13–26) | 22 (16–28) |
| HBV treatment | ||
| None‡ | 3 (2.6%) | 0 (0.0%) |
| Lamivudine alone | 3 (2.6%) | 0 (0.0%) |
| Tenofovir alone or in combination | 96 (84.2%) | 56 (90.3%) |
| Entecavir alone or in combination | 12 (10.5%) | 6 (9.7%) |
| cART including an anti-HBV nucleoside or nucleotide analogue, n (%) | 108 (94.7%) | 62 (100.0%) |
| Nucleoside/nucleote reverse transcriptase inhibitors | 109 (95.6%) | 60 (96.8%) |
| Non-nucleoside reverse transcriptase inhibitors | 38 (33.3%) | 23 (37.1%) |
| Protease inhibitors | 53 (46.5%) | 31 (50.0%) |
*
Data presented among this sample unless a subset is indicated due to missing data.
†
Unless otherwise indicated.
‡
One participant with a history of tenofovir use was not on any antiviral therapy at the time of the baseline assessment. One was on ritonavir, darunavir, emtricitabine, and dolutegravir. Another was on ritonavir alone.